丹参酮ⅡA磺酸钠注射液对非ST段抬高心肌梗死患者血浆组织型纤溶酶原激活物抑制物的影响

目的观察非ST段抬高心肌梗死患者血浆组织型纤溶酶原激活物抑制物（PAI-1）的变化和丹参酮ⅡA磺酸钠注射液对其的影响。方法将非ST段抬高心肌梗死患者136例随机分为治疗组72例和对照组64例。2组均予西药常规治疗,治疗组另加用丹参酮ⅡA磺酸钠注射液治疗。2组均14d为1个疗程。2组分别于治疗前、治疗后14d测定血浆PAI-1浓度,并观察其严重心律失常、心绞痛、心力衰竭的发生情况。结果治疗后2组PAI-1水平均下降（P〈0.05）,但治疗组下降更明显（P〈0.05）。治疗组严重心律失常、心绞痛、心力衰竭的发生率均显著低于对照组,差异均有统计学意义（P〈0.05）。结论丹参酮ⅡA磺酸钠注射液辅治非ST段抬高心肌梗死疗效确切,并能降低其严重心律失常、心绞痛、心力衰竭的发生率。

The effect of Sulfotanshinone sodium injection to plasminogen activator inhibitor-1 in patient with non-ST-segment elevatinon myocardial infarction

Objective To observe the change of plasminogen activator inhibitor-1（PAI-1） in patient with non-ST-segment elevatinon myocardial infarction（NSTEMI） and evaluate the efficacy of Sulfotanshinone sodium injection on it.Methods 136 cases patients with NSTEMI were randomly divided into treatment group（72 cases） and control group（64 cases）.Both groups were given conventional Western Medicine treatment,while the treatment group was given extra Sulfotanshinone sodium injection.All 14d for a course of treatment.Before and after treatment 14d,determined plasma PAI-1 concentrations,and observed the condition of severe arrhythmia,angina arrhythmia,heart failure of two groups.Results After treatment,PAI-1 level of two groups were decreased（P〈0.05）,but the treatment group decreased more significantly（P〈0.05）.The incidence rate of severe arrhythmia,angina pectoris and heart failure in treatment group were significantly lower than that in control group（P〈0.05）.Conclusion Sulfotanshinone sodium injection assisted treatment of NSTEMI is effective and can reduce the incidence rate of serious arrhythmias,angina,heart failure.